Olympus Capsule Endoscopy for Small Bowel Examination

Cristian Gheorghe, Razvan Iacob, Ion Bancila

Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest

Abstract

The video capsule endoscope has been developed to allow for direct examination of the small bowel in a safe, noninvasive and well-tolerated manner. The Olympus capsule endoscope, recently developed, with technology based on a charge-coupled device (CCD) and with electronic enhancement of image quality, differs from the Given capsule by a high-resolution CCD and an external real-time image viewer (External Viewer) monitor. The most frequent indications for video capsule endoscopy of the small bowel are the diagnosis of obscure gastrointestinal bleeding, angiodysplasia, Crohn’s disease, celiac disease, hereditary polyposis syndromes, small bowel tumors.

The following technical imaging review examines the current data and recent developments pertaining to diagnosis of small bowel lesions by video capsule endoscopy: indications, contraindications, diagnostic yield, spectrum of lesions.

Key words

Olympus capsule endoscopy - small intestine - celiac disease – angiodysplasia - Crohn’s disease

Introduction

Examination of the small bowel represents a challenge for endoscopists due to its length and inaccessibility using natural orifices. On the other hand, radiologic techniques are relatively insensitive for diminutive, flat, infiltrative or inflammatory lesions of the small bowel. The video capsule endoscope (VCE) has been developed to allow for direct examination of this inaccessible part of the gastrointestinal tract in a safe, noninvasive and well-tolerated manner and it has become the gold standard in the diagnosis of suspected diseases of the small bowel (1-3).
nistration of 2 liters of polyethylene glycol (PEG) solution in the evening and 1 liter 30 minutes before the procedure. The use of prokinetic agents (10 mg of metoclopramide) is optional in patients with slow gastric transit. Metoclopramide decreases gastric transit time and was recently shown to increase the likelihood of successful small bowel examination (7). In contrast, erythromycin had no significant effect on capsule propulsion in the small bowel (8). Patients are allowed to drink clear liquids 2 hours after ingestion of the capsule and to eat a light meal 4 hours after ingestion.

The Olympus EndoCapsule software provides a complex antenna consisting of eight antennas combined into one. The antenna receiving the strongest signal is highlighted and serves for the localization of capsule’s position in the gastrointestinal tract. The technology is considered imprecise, and locating the position of the capsule in the abdomen is judged considering also the mucosal patterns of the jejunum and ileum, the time elapsed from the start of the examination, and checking directly the capsule images during the procedure using the Olympus External Viewer (1).

The VCE software of Olympus EndoCapsule has a “multiview” capability added for reading the VCE recordings. This allows for the simultaneous display in adjacent windows of four consecutive images from the VCE recordings.

The Olympus EndoCapsule also includes software that detects the color red, which may help to identify bleeding in the small bowel.

**Clinical applications**

1. **Obscure gastrointestinal bleeding**

   The primary and most frequent indication for VCE of the small bowel is the diagnosis of obscure gastrointestinal bleeding. Obscure gastrointestinal bleeding represents approximately 5% of all gastrointestinal bleeds (9). It is defined as recurrent or persistent gastrointestinal bleeding despite the absence of explanatory findings at initial upper and lower endoscopy (10). Obscure gastrointestinal bleeding can be subclassified as either obscure-overt or obscure-occult bleeding, based on the history of gross gastrointestinal bleeding symptoms (melena or hematochezia). Obscure-occult gastrointestinal bleeding can be manifested by recurrent iron deficiency anemia, or by positive fecal occult blood test. The diagnostic yield reaches 92.3% for patients with ongoing-overt bleeding compared with 44.2% for obscure-occult bleeding and 12.9% for past bleeding (11). A recent consensus algorithm (12) suggest that VCE should be considered the first-line investigation for obscure bleeding, although second-look traditional endoscopy represents a reasonable approach, because up to 30% of lesions can be missed on the initial evaluation (13). Angiodysplasia (29%) (Fig.1), followed by unsuspected Crohn’s disease (6%) are the most frequent lesions which cause obscure gastrointestinal bleeding (14).

   Based on the findings from a recent study (15), the optimal timing for VCE investigation in obscure gastrointestinal bleeding is within the first few days post bleeding episode until a maximum waiting time of 2 weeks.

2. **Crohn’s disease**

   VCE has a high yield in detection of small bowel lesions in Crohn’s disease, allowing the diagnosis in a subset of patients with clinical suspicion but negative upper and lower endoscopy, including terminal ileum intubation (1). The diagnostic yield for this indication ranges from 43 to 71%, and according to recent studies VCE was superior to push enteroscopy (16) and enteroclysis (16,17). Because of the increased sensitivity of VCE compared with push enteroscopy and enteroclysis, it was designated as gold-standard examination for the diagnosis of small bowel Crohn’s disease (18). A meta-analysis of 9 prospective trials suggest a yield of 66% for VCE vs 24% for small bowel radiography and 46% for ileoscopy (19). Potential indications for the use of VCE in patients with suspected or established Crohn’s disease are: 1) suspected Crohn’s disease with negative upper endoscopy and colonoscopy; 2) evaluation of patients with indeterminate colitis; 3) evaluation of response to anti-inflammatory therapy, if indicated (20). There are few contraindications for VCE: 1) clinical or radiographic evidence of bowel obstruction; 2) extensive and active Crohn’s disease of the small bowel, with or without strictures; 3) intestinal pseudoobstruction; 4) extensive intestinal diverticulosis; 5) children under the age of 10 (20). The risk for VCE retention in patients with Crohn’s disease is estimated to 5% (1).

   The spectrum of lesions in the small bowel in Crohn’s disease ranges from erythema to aphthous, stellate or large ulcerations or fistulae (20) (Figs.2,3). There are more than 40 pathological conditions in which small bowel erosions or ulcers may be found. It is, therefore, important to exclude these conditions before the final diagnosis of Crohn’s disease is made. Erosions and ulcers of the small bowel may result from other causes/diseases such as NSAID intake (Fig.4), lymphoid hyperplasia, lymphoma, radiation enteritis, HIV with opportunistic infection, intestinal tuberculosis and Behçet’s disease. Finally, the diagnosis of Crohn’s disease should be based on the combination of clinical data and relevant findings of VCE (18).

3. **Celiac disease**

   Capsule endoscopy technology, with its magnification capacity of 1:8 and images taken very close to the mucosa, can provide good quality images of the small bowel, including the villi. The International Conference of Capsule Endoscopy has reached a consensus regarding the role of VCE in the diagnosis and complications of celiac disease (21). Capsule endoscopy may be useful in diagnosing celiac disease in patients with new or persistent symptoms or suggestive serological markers for celiac disease who are unwilling or unable to undergo an upper gastrointestinal endoscopy. The abnormalities detected include primary diagnostic changes in small bowel mucosa (endoscopic
Fig. 1 Angiodysplastic lesion of the small bowel mucosa.

Fig. 2 Crohn’s disease: small bowel ulcers.

Fig. 3 Crohn’s disease: aphtoid lesion.

Fig. 4 Small ulcerations after NSAID ingestion.

Fig. 5 Celiac disease: Scalloping of folds.

Fig. 6 Celiac disease: Mosaic appearance of the small bowel mucosa.

Fig. 7 Celiac disease: Flat mucosa with visible vessels.

Fig. 8 Celiac disease: Abnormal villi, thickened and shortened.
The terminology used to describe villous atrophy is also applied to VCE: scalloping (Fig.5), fissuring, mosaic pattern (Fig.6), flat mucosa (Fig.7), abnormal villi – shortened and thickened (Fig.8), layered or stacked folds (Fig.9), loss of circular folds and nodularity (Fig.10) (22,23), and complications related to celiac disease such as ulcerative jejuno-ileitis, enteropathy-associated T-cell lymphoma and adeno-carcinoma of the small bowel (24,25). The sensitivity and specificity of VCE for recognizing villous atrophy is 70% and 100%, respectively. For diagnosing complications of long standing celiac disease (lymphoma, ulcerative jejunitis, adeno-carcinoma), VCE should be performed early in patients who develop evoking symptoms such as diarrhea, abdominal pain, fever, or evidence of gastrointestinal bleeding (23). Candidates for surveillance for malignancy include elderly patients recently diagnosed with celiac disease (increased risk for lymphoma), as well as individuals diagnosed in childhood who are reconfirmed as adults (increased risk for adenocarcinoma) (26).

4. Hereditary polyposis syndromes

Many gastrointestinal polyposis syndromes include small bowel polyps as part of clinical presentation. 30% to 50% of patients with severe polyposis will develop small bowel adenocarcinomas. VCE is a simple, safe and non-invasive procedure for the detection of small bowel polyps related to hereditary polyposis syndromes (Fig.11). Growing evidence confirms the usefulness of this technique for detecting polyps in selected patients with familial adenomatous polyposis, who have an increased risk of developing polyps in the distal part of the small bowel (patients with severe duodenal polyposis, 2-4 Spigelman score) (28-30), and as first-line procedure in patients with Peutz-Jeghers syndrome (31). VCE has been found to have higher, respectively similar accuracy as compared with barium studies and magnetic resonance imaging (MRI) for the detection of large polyps (>15 mm) in patients with hereditary polyposis syndromes. However, the detection rate for small (5-15 mm diameter) and diminutive (<5 mm) polyps is much higher with VCE (27). Schulmann et al recently showed that approximately 20% of patients with hereditary polyposis syndromes had polyps in the distal jejunum or ileum that were beyond the reach of upper and lower traditional endoscopy, detected only by VCE (28).

5. Small bowel tumours

The most common indication for VCE in patients with small bowel tumours is obscure gastrointestinal bleeding (80%) (Fig.12). The majority of detected small bowel tumors are malignant (60%), consisting of adenocarcinomas, melanomas, carcinomas, lymphomas, and sarcomas. The benign small bowel tumours (40%) are gastrointestinal stromal tumors, hemangiomas, hamartomas, and adenomas (1).

6. Miscellaneous

Various small bowel lesions have been described using VCE: Meckel’s diverticulum, tuberculosis, Ascaris infection,
and aortoduodenal fistulae. VCE was also used in some centers for the assessment of bowel in post transplant recipients, unexplained abdominal pain and diarrhea (1). In addition to enhanced resolution of the CCD-captured endoscopic images, the real time image interpretation on a LCD display could be useful for detecting the gastric transit abnormality as well as for increasing the likelihood of a complete small bowel examination in patients undergoing Olympus VCE system (6,32).

Disclosure
There are no conflicts of interest.

Grant
This study was supported by a research grant of the Romanian Ministry of Research - VIASAN 428/2004 (COLOCANS).

References
11. Fireman Z. The light from the beginning to the end of the tunnel. Gastroenterology 2004; 126: 914-916
13. Eisen GM. Capsule endoscopy indication. ASGE Clinical Update 2006; 14: 1-4